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Background: Sarcoidosis is a multisystem granulomatous disorder of unknown etiology, characterized by “non-caseating granulomas” in different organs. Clinical signs are variable and dependent on the organ involved. In athletes it is often  asymptomatic, however, considering  the high level of athletic performance and the related  risks  due to  the  potential  heart involvement, a  particular diagnostic  flow-chart  to consider some  other  diagnosis it  is required. The  present  case  report  is  aimed to focus  on  the clinical approach in  case of  a  progressive weakness associated  to a  reduction of global performance in  an athlete. Case Presentation: Since October 2008 a 33-year-old Scandinavian professional soccer player has been showed splitting headache, fever, and impaired exercise tolerance.  Despite some  clinical  aspects  and  symptoms, according to the   current guidelines,   could   address toward a  granulomatosis  diagnosis,   the first hypothesis was indicative for a possible viral infection and  therefore the  athlete  had got a drug-therapy resolving the headache and the fever. However in consequence of persisting  of the  weakness, several else clinical possibilities were evaluated following  a more  complete   diagnostic flow-chart blood  and instrumental exams. Conclusion: This   case report   focuses on   the substantial absence of  symptoms  during the  granulomatosis disease. The differential diagnosis  results  to be often  complicated  and requires several  additional exams in order to establish  the presence of “Non-evolutive sarcoidosis- stage I”  , where the  therapy is  not mandatory.  





Sarcoidosis is a multisystem disease at unknown etiology, characterized by the presence of “non caseating granulomas” in several organs. Despite the exact prevalence of sarcoidosis is not yet  known, its  incidence,  in people  like black Americans and Scandinavians, is higher  than in others (1,2,3). The greatest incidence is in young adults aged 20 – 40 and also athletes can be involved with an evident reduction of their sport performance. For  almost  the 50% of the patients affected, the diagnosis is often casual or occasional  in case of  the evidence of pulmonary radiographic abnormalities. Actually the accurate etiology of the disease is not exactly known. It has been supposed that it can be mainly found in susceptible subjects, as a consequence of an  inflammatory response of  organism to external inputs. The possible causes of immunologic response could be infective (viral, bacterial or mycobacterial), or due to  the inhalation of organic and inorganic agents. The inflammatory response is therefore  characterized by accumulation of T-lymphocytes and macrophages, with consequent organization in granulomas (4). According  to the current  guidelines (4) the diagnosis of Sarcoidosis is actually based on the presence of  typical symptoms (fever, fatigue, malaise, asthenia, dyspnea, cough, polyarthralgia, lymphadenopathy), high plasma level of  a peculiar  enzyme  i.e. Angiotensìn Converting Enzyme (ACE), presence of a  bilateral hilar lymphadenopathy  at the standard  chest  radiological  exam  and  histological evidence  of  non caseating epithelioid cell granulomas (4).  In order to  confirm the  diagnosis, some  additional  laboratory and  instrumental exams ( Purified Protein  Derivative (PPD) skin test; serum level of erythrocyte sedimentation rate (ESR), C-reactive protein (PCR), Calcium, Phosphate; Kveim’s reaction test; complete microbiologic  tests, Holter monitoring, echocardiography and thallium or gallium scans, Magnetic resonance imaging (MRI), head CT scans for the  central nervous system  and  myocardial involvement, can be helpful (4). Despite  the most typical symptoms of sarcoidosis, include cough, dyspnea  thoracic pain, fever and the weakness, a substantial  absence  of  symptoms can be found    in the 90% of patients where  the  bilateral hilar adenopathy and interstitial or alveolar opacities were often evident Just in case of seriousness big conglomerate clusters of granulomas, especially in the upper parts of lungs,  the symptoms, due to the  presence  of the  stenosis or bronchiectasis, can be found (5). Otherwise  in athletes, the involvement  of different organs and tissues is frequent:  in the 10%  of them the skeletal-muscle system with acute polyarthritis, especially in hips can be interested and also tendons and peritendineus tissue can be affected  by a degenerative process that can outcome in a breaking, especially in case of protracted stress. The cardiac injure regards more frequently the female Japan population (approximately 20-47% of patients). This aspect determines the 85% of sarcoidosis deaths, however  the symptoms  are observed  only the 5% of cases and the survival up to five years  are  evident in about the 60% of the subjects (6). A cardiac sarcoidosis, characterized by wide fibrotic areas, can involve  the pericardium, the  endocardium, or  the myocardium areas, mainly in  the free wall of the left ventricle and in the interventricular septum creating   some possible arrhythmias   (from the first grade atrioventricular block up to a complete block, atria arrhythmias, ventricular tachycardia  sustained or not sustained) due to a reentry loop(7). A potential evolution toward the left ventricle dilatation with heart failure has been  also  described (8,9,10). The diagnosis of cardiac sarcoidosis is possible by the electrocardiographic, echocardiographic and radionuclide investigations (Gadolinium MRI exam), but  the gallium-67 citrate (Ga) or Thallium-201 scintigraphy are normally  used to assess the activity of  the disease and the response  to  the corticosteroid therapy (11, 12, 13). The cardiac biopsy is  normally avoided  for the high level of risk associated  respect to a low sensitivity (14). In conclusion  the chest XR  is generally the first exam to support a diagnosis of sarcoidosis but in case of doubt a chest CT, with  the  addition of the bioptic sampling can be helpful to identify the granulomas and also to perform the differential diagnosis among  others “granulomatous diseases”. The respiratory functional tests remain however the main tests to estimate the disease’s severity showing  normal values at the first stages while a restriction pattern with a reduced diffusion of CO in advanced stages (15). 
Case Presentation 
The patient gave his oral consent   to use the  clinical  data  for the  presentation  of the case report. 
Since October 2008 a 33-years-old Scandinavian professional soccer player has been showed splitting headache with fever and meningitic irritation’s signs like photophobia.
The first diagnostic hypothesis was  addressed toward an Virus Toscana  infection  that is frequent in this area.  Initially all the serologic tests were negative: only a slight increase  of ACE  and unspecific flogosis-indexes  like ESR and CRP were  evident;  head CT scans  and magnetic resonance angiography (MRA) were negative too.  Despite  these results, he was nevertheless   submitted to a corticosteroid therapy with the resolution of the headache and the fever. However, persisting  a strong weakness with an inevitable  negative impact on his sporting performance, some others possible causes of the asthenia were considered  and evaluated  following  an additional diagnostic flow-chart.  The examinations made during one more month  spent in an  hospital, showed normal values of  the general  blood tests, none  serological signs  of lymphoma while a little increase of ACE plasma level was observed.  The serologic tests by polymerase chain reaction technique ( PCR),  including  PPD skin test, resulted to be  negative  with exception of a past  Toscana Virus (IgG) infection .  
Among the  cardiological investigations, the echocardiographic exam was normal while   Maximal Ergometric Test (MET) showed  sporadic, singular monomorphic ventricular extrasystoles and in addition, the 24 hours monitoring ECG Holter  showed  some  polymorphic ventricular extrasystoles,  partially organized in short bigeminal rhythm, and monomorphic and polymorphic  couples at rest condition.
The respiratory functional tests described  a pattern compatible with a  slight obstruction, normal CO diffusion; the chest XR  was characterized by a moderate parenchyma involvement  due to an hilar lymphadenopathy (​http:​/​​/​en.wikipedia.org​/​wiki​/​Lymphadenopathy" \o "Lymphadenopathy​) (Fig 1, Fig 2). The abdominal echography, showed  an enhancement of the liver and spleen dimensions, with the presence of abdominal lymph nodes, whose presence was confirmed by the abdominal and chest CT ( Fig 3) , where an  the increase of inguinal, mediastinal, supraclavicular and cervical lymph nodes, with the same pattern were also described  ( Fig 4) . The additional evaluation by  Positron  Emission  Tomography (PET/CT),  showed a  mediastinal   and supraclavicular areas with high glucose-metabolism; lower in the others. In the meantime, the athlete was quite asymptomatic, and the weakness was the sign more constant. Therefore a diagnosis of sarcoidosis was  supposed. The athlete was submitted to a bioptic sampling  of  the laterocervical lymph nodes confirming  the diagnosis previously  hypothesized. The lymph  nodes resulted in fact  affected by “non caseating granulomas”.  Considering the quite good clinical condition of the athlete, no more additional pharmacologic therapy was suggested,  but one month of detraining was advised. Thirty days later he was in fact in a fairly good physical state and the follow-up exams didn’t show any more progression of the disease. After four months he gradually restarted his training and actually he is in good performances.  
 Discussion
 The symptom “asthenia” in a professional athlete is often described as loss of his  global performance. In case of  “unspecific symptoms “  like headache, muscular fatigue and fever, it is necessary  to reduce the time of sportive seasonal training to avoid the negative consequences of  the overtraining.  When it is possible to exclude any relationship  between  symptoms and  sport activity, it is correct to suspect a common pathology as flu syndrome or infective pathologies. Otherwise,  according  to previous  examples of  cases  report   (22,23) where exclusively  unspecific clinical  symptoms  are  evident, when the most common  pathologies can be excluded, some other diseases as lymphoma, tuberculosis, rheumatoid arthritis,  rheumatic fever and mycosis have to be considered.   When also these ones  can  be excluded ,  it is consequently lawful to think to sarcoidosis. Fatigue is the most common and the major problem in young patients with sarcoidosis, submitted  or not  submitted to  a corticosteroid therapy.   It is very difficult to evaluate this aspect,  because no direct relationship between fatigue and clinical parameters is  often  evident, and no standard quantification  of these symptoms  are yet available. The Fatigue Assessment Scale (FAS), and the 6-minutes walk  (15, 16, 17)  can be considered now as the exclusive valid instruments to assess this one and able to show the impaired exercise tolerance, due to multiple factors above (18, 19, 20). The sarcoidosis can often  involve  unexpected organs (22,23)  and only  the evidence of non-caseating granulomas can confirm  the doubt . 
 The correct diagnosis of sarcoidosis is therefore possible following a flow-chart to obtain   a   complete differential diagnosis panel, considering the presence of symptoms, the radiologic signs associated in addition  to an  histopathologic confirmation. After the anamnesis and the physical examination several else exams are therefore necessary:
o	Complete blood tests
o	ECG, echocardiogram, ECG sec. Holter
o	Respiratory functional tests
o	Chest XR
o	Chest CT: especially in advanced stages of disease, when the radiologic images can be simulate pulmonary metastasis
o	IMR or scintigraphy with Gallium-67 or Tallium-201
o	Transbronchial bronchoscopy biopsy

The 90% of patients has a spontaneous resolution after two years, while in less than 10% of them a restarting of the disease is evident; on the contrary, in the 30% of the cases, the sarcoidosis becomes chronic, with permanent issues. The symptomatic subjects are normally submitted to a corticosteroid therapy (Prednisone 0,3-1 mg/Kg/die until a maximum of 40 mg/die).  If the patient shows a good resolution of the disease within the first two weeks of therapy, he can be considered a “responder”.  A restart of  the disease activity is possible when the corticosteroid therapy  is interrupted.
Conclusions 
The  data  obtained   attend to to a “sarcoidosis on first stage”, actually not yet developed and  exclusively characterized by a clinical manifestation: i.e. the persistent asthenia.
 This case report supports the assumption that in asymptomatic subjects, the therapy is not normally necessary.  The Rx monitoring the respiratory functional tests and the blood markers of disease are often sufficient, especially when the symptoms are  restricted to a weakness. A variable period of de-training is, in fact, sufficient to restitute the performance previously lost. 
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Fig 1,2: The  pictures of the chest by XR  exam in two  different visualizations, show the pulmonary involvement   due to an hilar lymphadenopathy (​http:​/​​/​en.wikipedia.org​/​wiki​/​Lymphadenopathy" \o "Lymphadenopathy​).
Fig3:  The CT image shows the presence of inguinal lymph nodes.
Fig 4: The CT image shows the increase of  mediastinal lymph nodes.











